News: PIQ Proteomics international laboratories signs production contract with Monash Antibody..., page-3

Good on ya Chev
I've had these bad boys since their IPO. It seems the market doesn't understand the impact PromarkerD will have in succcessful early detection resulting in subsequent treatment of diabetes.
Proteomics is clearly a medical technology being recognised as the best method to accurately and efficiently analyse a raft of different health problems. Luckily for us - and proudly so, PIQ is paving the way in identifying these markers to identify diseases. Obviously the result of this is profits. A current share price of 0.29 is ridiculously cheap considering this company's massive potential. Not to mention their very clever positioning in China and India where rates of diabetes is increasing at alarming rates.. we're looking at a multi billion dollar industry and exceptional returns for investors.

I'm stoked

Sit tight.. and enjoy.

Snow.